Experience
Teva Pharmaceutical Industries Ltd.
AstraZeneca Pharmaceuticals LP
The United States District Court for the Eastern District of Pennsylvania granted summary judgment of patent invalidity due to prior invention thereby terminating an action that Teva Pharmaceutical Industries Ltd. brought against firm clients AstraZeneca Pharmaceuticals, Inc. and several other AstraZeneca entities. Teva alleged that its patent covered AstraZeneca’s blockbuster anti-cholesterol drug, Crestor®, and sought damages and fees. AstraZeneca moved for summary judgment of invalidity due to its prior invention of the Crestor® formulation. Judge William H. Yohn, Jr. found that AstraZeneca had invented first and had not abandoned, suppressed, or concealed its invention. Accordingly, Judge Yohn invalidated all asserted claims of Teva’s patent and entered judgment in AstraZeneca’s favor.
Teva Pharmaceutical Industries Ltd. v. AstraZeneca Pharmaceuticals LP, 2:08-cv-04786, E.D. Pa., Judge Yohn
Teva Pharmaceutical Industries Ltd. v. AstraZeneca Pharmaceuticals LP, 11-1091, Fed. Cir., Judges Dyk, Linn, Rader
The Hillman Group, Inc. v. KeyMe, LLC
The Hillman Group, Inc.
Bright Data Ltd. v. NetNut Ltd.
NetNut Ltd.
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
American Regent, Inc.
Delta Faucet Company v. Globe Union Industrial Corp. et al.
Globe Union Industrial Corp.
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Eureka Database Solutions, LLC v. Nexidia, Inc.
Nexidia, Inc.
Guntert & Zimmerman Const. Div., Inc. v. GOMACO Corporation
GOMACO Corporation
Hawk Technology Systems, LLC v. Kirkland's Inc.
Kirkland's Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.